Sign in

IMGN on NASDAQ

ImmunoGen Inc.

Biotechnology company

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts. An ImmunoGen ADC contains a manufactured antibody that binds to a target found on cancer cells, with one of the company's potent cell-killing agents attached as a "payload".3 Its shares trade on NASDAQ under the symbol IMGN.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1981Founded1

Compare with UroGen Pharma Ltd., Theravance Biopharma, Inc. or ZEVRA THERAPEUTICS, INC., or pick any stock.

  • TickerIMGN on NASDAQ1
  • IndustryPharmaceutical Preparations1
  • HeadquartersWaltham1
  • Websitewww.immunogen.com
  • Incorporated inMA5
  • Business address830 Winter St, Waltham, Ma 024515
  • Filer categoryLarge accelerated filer5
  • Legal formDomestic Business Corporation4
  • LEI54930084U0R1OP766Y024
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O Craig Barrows, 02451 Waltham, United States4
  • Registered withCorporations Division (Secretary of the Commonwealth's Office), 0427266914

See how the biggest companies compare on our leaderboards

ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen was founded in 1981 and was headquartered in Waltham, Massachusetts.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-203.1%Operating margin7
-204.9%Net margin7
55.7%Revenue growth, 20227
-143.1%Return on equity7
-$231.2MFree cash flow7

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development65¢$213.4M
  • Selling, general and admin35¢$116.1M
  • Income tax0¢$1.2M

Out of $108.8M in revenue.7 The company lost money this year.

Financial statements

Revenue89107$108.8M in 2022+124% since 2016
0$50.0M$100.0M$150.0M2016: $48.6M$48.6M20162017: $115.4M$115.4M2017+137%2018: $53.4M$53.4M2018−54%2019: $82.3M$82.3M2019+54%2020: $132.3M$132.3M2020+61%2021: $69.9M$69.9M2021−47%2022: $108.8M$108.8M2022+56%
Operating income11129107-$220.9M in 2022+63% since 2016
-$300.0M-$200.0M-$100.0M02016: -$135.6M-$135.6M20162017: -$59.0M-$59.0M2017−57%2018: -$161.4M-$161.4M2018+174%2019: -$92.2M-$92.2M2019−43%2020: -$22.4M-$22.4M2020−76%2021: -$125.1M-$125.1M2021+459%2022: -$220.9M-$220.9M2022+77%
Net income11129107-$222.9M in 2022+42% since 2016
-$300.0M-$200.0M-$100.0M02016: -$156.7M-$156.7M20162017: -$96.0M-$96.0M2017−39%2018: -$168.8M-$168.8M2018+76%2019: -$104.1M-$104.1M2019−38%2020: -$44.4M-$44.4M2020−57%2021: -$139.3M-$139.3M2021+214%2022: -$222.9M-$222.9M2022+60%
Fiscal year2016201720182019202020212022
Revenue$48.6M8$115.4M8$53.4M9$82.3M10$132.3M7$69.9M7$108.8M7
Research and development$141.3M11$139.7M12$174.5M9$114.5M10$114.6M7$151.1M7$213.4M7
Selling, general and admin$38.6M7$43.8M7$116.1M7
Operating expenses$194.9M7$329.7M7
Operating income-$135.6M11-$59.0M12-$161.4M9-$92.2M10-$22.4M7-$125.1M7-$220.9M7
Income before tax-$139.3M7-$221.7M7
Income tax$012$09$010$07$07$1.2M7
Net income-$156.7M11-$96.0M12-$168.8M9-$104.1M10-$44.4M7-$139.3M7-$222.9M7
Earnings per share-$0.7010-$0.257-$0.687-$0.887
Earnings per share (diluted)-$0.7010-$0.257-$0.687-$0.887
Shares (weighted, basic)206.1M shares7253.6M shares7
Shares (weighted, diluted)206.1M shares7253.6M shares7

Compare ImmunoGen Inc. with another company

Corporate structure

ImmunoGen Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of ImmunoGen Inc.

  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on ImmunoGen Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • Redmile Group, LLC Filed SC 13G/A on ImmunoGen Inc., latest Feb 14, 2024 (3 filings since Feb 14, 2022)
  • VANGUARD GROUP INC Filed SC 13G/A on ImmunoGen Inc., latest Feb 13, 2024 (3 filings since Feb 10, 2022)
  • ADAGE CAPITAL PARTNERS GP, L.L.C. Filed SC 13G/A on ImmunoGen Inc., latest Feb 7, 2024 (3 filings since Apr 4, 2022)
  • BlackRock Filed SC 13G/A on ImmunoGen Inc., latest Jan 25, 2024 (4 filings since Feb 8, 2022)
  • State Street Corporation Filed SC 13G/A on ImmunoGen Inc., latest Jan 22, 2024 (2 filings since Feb 8, 2023)
  • James E. Flynn Filed SC 13G/A on ImmunoGen Inc., latest Feb 10, 2023 (2 filings since May 19, 2022)
  • FMR LLC Filed SC 13G/A on ImmunoGen Inc., latest Feb 9, 2023 (2 filings since Feb 9, 2022)
  • Wellington Management Company Filed SC 13G/A on ImmunoGen Inc., latest Feb 6, 2023 (2 filings since Jan 10, 2022)
  • ImmunoGen Inc. Waltham, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What ImmunoGen Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$35.7M7 Dec 31, 2022$34.4M7 Dec 31, 2021+4.0%
Accumulated depreciation$31.4M7 Dec 31, 2022$29.7M7 Dec 31, 2021+5.6%
Property and equipment, net$4.4M7 Dec 31, 2022$4.7M7 Dec 31, 2021−6.1%
Operating-lease assets (leased space)$10.2M7 Dec 31, 2022$12.4M7 Dec 31, 2021−17.4%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$275.1M7 Dec 31, 2022$478.8M7 Dec 31, 2021−42.5%

Leadership

Who has led ImmunoGen Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Mitchel Sayare2006–2008
  2. Daniel M. Junius2009–2016
  3. Mark J. Enyedy2016–2024

Chair

  1. Mitchel Sayare2009

President

  1. Craig Barrows2010–2019

Chief financial officer

  1. Daniel M. Junius2006–2008
  2. Gregory D. Perry2009–2013
  3. Susan Altschuller2020–2022
  4. Lauren White2023–2024
1990200020102020
Board members and other officers (36)

Products and brands

Currently approved ADCs with ImmunoGen technology employ one of the company's maytansinoid cell-killing agents, either DM1 or DM4, or one of the company's DNA-acting IGN payloads.

DM1 attached to an antibody with ImmunoGen's thioether linker is called "emtansine" in its INN name

trastuzumab emtansine, marketed as Kadcyla

DM1 attached to an antibody with ImmunoGen's SPP linker is called "mertansine".

Read the full text

DM4 attached with ImmunoGen's SPDB linker is called "ravtansine"

indatuximab ravtansine (BT062) targeting multiple myeloma,

anetumab ravtansine (BAY94-9343) targeting mesothelin (to treat mesothelioma), starting phase II trial in 2016

coltuximab ravtansine (SAR3419) targeting CD19 to treat acute lymphoblastic leukemia (ALL).

DM4 attached with ImmunoGen's sSPDB linker is called "soravtansine"

mirvetuximab soravtansine

ImmunoGen also developed isatuximab, a monoclonal antibody without linkage to a toxin.

From Wikipedia’s article on ImmunoGen, shared under CC BY-SA 4.0.6

Former names

  • IMMUNOGEN INCFeb 14, 1994 to Aug 5, 20195

Timeline

  1. Feb 12, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer55
  2. Feb 8, 20248-K Other events56
  3. Jan 31, 20248-K Shareholder vote57
  4. Jan 29, 20248-K Other events58
  5. Jan 24, 20248-K Other events59
  6. Jan 8, 20248-K Other events60
  7. Nov 30, 20238-K Entered a material agreement; Other events61
  8. Nov 2, 20238-K Results of operations62
  9. Sep 18, 20238-K Executive or director change; Regulation FD disclosure63
  10. Jul 31, 20238-K Results of operations64
  11. Jun 16, 20238-K Bylaws or fiscal year changed; Shareholder vote65
  12. May 5, 20238-K Entered a material agreement; Other events66
  13. May 19, 2016New chief executive Mark J. Enyedy becomes CEO15
  14. Jan 5, 2009New chief executive Daniel M. Junius becomes CEO16
  15. Feb 1, 2006New chief executive Mitchel Sayare becomes CEO17
  16. Mar 26, 1990Went public Listed on NASDAQ1
  17. 1981Founded Founded1

Calendar

When it reported results

  1. Nov 2, 2023Reported quarterly or annual results62
  2. Jul 31, 2023Reported quarterly or annual results64
  3. Apr 28, 2023Reported quarterly or annual results67
  4. Mar 1, 2023Reported quarterly or annual results68
  5. Jan 9, 2023Reported quarterly or annual results69
  6. Nov 4, 2022Reported quarterly or annual results70
  7. Jul 29, 2022Reported quarterly or annual results71
  8. May 6, 2022Reported quarterly or annual results72

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

311 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 36 major events, 148 insider forms, 24 large holders, 94 other. The latest 20:

  1. Feb 22, 202415-12G EDGAR
  2. Feb 14, 2024SC 13G/A EDGAR
  3. Feb 14, 2024SC 13G/A EDGAR
  4. Feb 13, 2024SC 13G/A SCHEDULE 13G/A EDGAR
  5. Feb 12, 202425-NSE EDGAR
  6. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  7. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  8. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  9. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  10. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  11. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  12. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  13. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  14. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  15. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  16. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  17. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  18. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  19. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR
  20. Feb 12, 20244 OWNERSHIP DOCUMENT EDGAR

The 311 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

26 open-market trades by officers, directors and large owners since October 2021: 0 buys and 26 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Feb 5, 2024Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale4,583$29.30$134.3KForm 4
Feb 5, 2024Wingrove TheresaSVP OF REGULATORY AFFAIRSSale12,027$29.30$352.4KForm 4
Feb 5, 2024Enyedy Mark JCHIEF EXECUTIVE OFFICERSale20,107$29.28$588.7KForm 4
Feb 5, 2024Lentini ReneeVP & PRIN ACCTG OFFICERSale2,631$29.30$77.1KForm 4
Jan 16, 2024Wingrove TheresaSVP OF REGULATORY AFFAIRSSale187,667$29.64$5.6MForm 4
Dec 26, 2023Lentini ReneeVP & PRIN ACCTG OFFICERSale6,548$29.74$194.7KForm 4
Dec 15, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale117,445$29.40$3.5MForm 4
Nov 30, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale3,826$29.20$111.7KForm 4
Nov 30, 2023Peterson KristineDirectorSale20,000$28.90$578.0KForm 4
Nov 30, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale164,424$28.95$4.8MForm 4
Nov 29, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale6,792$16.66$113.2KForm 4
Nov 17, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale78,223$16.05$1.3MForm 4
Nov 16, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale4,100$16.01$65.6KForm 4
Nov 15, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale166,725$15.85$2.6MForm 4
Nov 15, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale26,286$16.01$420.8KForm 4
Nov 7, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale19,517$16.66$325.2KForm 4
Nov 6, 2023Lentini ReneeVP & PRIN ACCTG OFFICERSale219,545$15.29$3.4MForm 4
Oct 16, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale192,004$14.40$2.8MForm 4
Sep 15, 2023Wingrove TheresaSVP OF REGULATORY AFFAIRSSale192,013$15.44$3.0MForm 4
Aug 9, 2023Coen Stacy AnnSVP & CHIEF BUSINESS OFFICERSale100,210$14.20$1.4MForm 4

All 26 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How ImmunoGen Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARImmunoGen, Inc.2
  • CIK0000855654
  • Employer ID (EIN)04-27266912
  • Filer statusLarge accelerated filer2
  • Incorporated inMassachusetts2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2834 Pharmaceutical Preparations2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address830 Winter St, Waltham, MA 024512
  • Phone(781)895-06002
  • Shares outstanding266,264,274 as of Oct 25, 202314
  • Public float$989.7M as of Jun 30, 20227
  • On EDGAR sinceFeb 14, 19942
  • Filings1,766 in all: 4 (741), 8-K (349), SC 13G/A (110), 10-Q (86), 144 (51), 3 (45), SC 13G (37), CT ORDER (32)2
    All 46 form types

    S-8 POS (30), DEF 14A (29), DEFA14A (25), S-8 (25), 10-K (24), 424B5 (23), 4/A (19), 10-Q/A (14), 424B3 (13), CORRESP (13), S-3 (13), UPLOAD (13), ARS (10), S-3/A (10), PRE 14A (8), 8-K/A (6), 10-K405 (4), EFFECT (4), S-3ASR (4), SC 13D/A (4), 10-K/A (3), 10-C (2), 424B2 (2), DEFS14A (2), PRES14A (2), 10-KT (1), 15-12G (1), 25-NSE (1), 3/A (1), 424B1 (1), 5 (1), DEFM14A (1), DEL AM (1), FWP (1), NT 10-K (1), POS AM (1), PREM14A (1), SC 13D (1)

  • Latest filingsAnnual report (10-K) Mar 1, 2023
    Quarterly report (10-Q) Nov 2, 2023
    Proxy statement (DEF 14A) Apr 26, 2023
    Latest 8-K (8-K) Feb 12, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
    SEC EDGAROther events
  57. 57
  58. 58
    SEC EDGAROther events
  59. 59
    SEC EDGAROther events
  60. 60
    SEC EDGAROther events
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81